Perspective Therapeutics, Inc. (CATX)
0.78
-0.08
(-9.29%)
USD |
NYAM |
Nov 18, 16:00
0.7902
+0.01
(+1.31%)
After-Hours: 20:00
Perspective Therapeutics Enterprise Value : -99.85M for Nov. 17, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 17, 2026 | -99.85M |
| November 16, 2026 | -92.55M |
| November 13, 2026 | -90.35M |
| November 12, 2026 | -101.85M |
| November 11, 2026 | -103.81M |
| November 10, 2026 | -108.24M |
| November 09, 2026 | -100.34M |
| November 06, 2026 | -102.12M |
| November 05, 2026 | -108.01M |
| November 04, 2026 | -98.67M |
| November 03, 2026 | -97.55M |
| November 02, 2026 | -79.29M |
| October 30, 2026 | -66.73M |
| October 29, 2026 | -64.45M |
| October 28, 2026 | -55.31M |
| October 27, 2026 | -62.16M |
| October 26, 2026 | -59.88M |
| October 23, 2026 | -14.22M |
| October 22, 2026 | 59.99M |
| October 21, 2026 | 64.55M |
| October 20, 2026 | 64.55M |
| October 19, 2026 | 52.00M |
| October 16, 2026 | 49.71M |
| October 15, 2026 | 69.12M |
| October 14, 2026 | 57.71M |
| Date | Value |
|---|---|
| October 13, 2026 | 61.13M |
| October 12, 2026 | 89.67M |
| October 09, 2026 | 105.65M |
| October 08, 2026 | 111.36M |
| October 07, 2026 | 82.82M |
| October 06, 2026 | 71.40M |
| October 05, 2026 | 95.38M |
| October 02, 2026 | 117.07M |
| October 01, 2026 | 112.50M |
| September 30, 2026 | 115.93M |
| September 29, 2026 | 65.99M |
| September 28, 2026 | 52.30M |
| September 25, 2026 | 54.58M |
| September 24, 2026 | 52.30M |
| September 23, 2026 | 65.99M |
| September 22, 2026 | 104.78M |
| September 21, 2026 | 105.92M |
| September 18, 2026 | 95.66M |
| September 17, 2026 | 95.66M |
| September 16, 2026 | 75.12M |
| September 15, 2026 | 78.54M |
| September 14, 2026 | 100.22M |
| September 11, 2026 | 87.67M |
| September 10, 2026 | 83.11M |
| September 09, 2026 | 108.20M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Anika Therapeutics, Inc. | 153.30M |
| MiMedx Group, Inc. | 343.25M |
| T2 Biosystems, Inc. | -- |
| ABVC BioPharma, Inc. | 27.84M |
| Enovis Corp. | 2.902B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -32.44M |
| Revenue (Quarterly) | 0.02M |
| Total Expenses (Quarterly) | 32.46M |
| EPS Diluted (Quarterly) | -0.2687 |
| Gross Profit Margin (Quarterly) | -5.86K% |
| Profit Margin (Quarterly) | -162.2K% |
| Earnings Yield | -160.0% |
| Normalized Earnings Yield | -147.90 |